Metoprololsuccinat Polpharma

Metoprolol Tartrate, the active ingredient in Metoprololsuccinat Polpharma, is a beta blocker presented as a tablet for oral use. It treats hypertension, angina pectoris, post‑myocardial infarction, chronic heart failure and certain cardiac arrhythmias in adult patients. The medication is indicated for long‑term management of cardiovascular disease and is administered under physician supervision.

GNH USA supplies Metoprololsuccinat Polpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing regulated quality‑assured batches through established distribution networks and supporting timely delivery.

Metoprolol Tartrate is used to manage cardiovascular conditions that involve elevated blood pressure or cardiac workload.

Hypertension: lowers systemic blood pressure and reduces cardiovascular risk. Angina pectoris: decreases myocardial oxygen demand, relieving chest pain. Post‑myocardial infarction: improves survival and reduces recurrence of cardiac events. Chronic heart failure: lowers mortality and hospitalisation rates. Certain cardiac arrhythmias: controls heart rate and stabilises rhythm.

Metoprolol Tartrate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Fatigue or tiredness - Dizziness or light‑headedness - Bradycardia (slow heart rate) - Cold extremities or peripheral circulation changes - Gastrointestinal upset such as nausea or abdominal discomfort - Sleep disturbances or vivid dreams

Serious or Rare Side Effects: - Severe bradycardia or heart block - Marked hypotension - Bronchospasm, especially in patients with asthma or COPD - Depression or significant mood changes - Allergic reactions including rash, angioedema, or anaphylaxis - Worsening heart failure or pulmonary edema

When prescribing Metoprolol Tartrate, clinicians should consider several safety measures.

Monitor blood pressure: check regularly to avoid excessive hypotension. Assess heart rate: watch for bradycardia, especially in patients with conduction disorders. Evaluate respiratory status: use cautiously in patients with asthma or COPD. Review renal and hepatic function: dose may need adjustment in impairment. Consider drug interactions: avoid concurrent use with other β‑blockers or certain calcium‑channel blockers. Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Metoprolol Tartrate can interact with a variety of medicines, requiring careful management.

Major Interactions (Avoid): - Concomitant non‑selective β‑blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): risk of severe bradycardia and AV block. - Antidiabetic agents: may mask hypoglycaemia symptoms. - MAO inhibitors: can enhance bradycardic effect. - Clonidine abrupt withdrawal: may cause rebound hypertension.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may increase risk of hypotension. - Diuretics: enhance blood‑pressure‑lowering effect. - NSAIDs: may reduce antihypertensive efficacy. - Anticholinergic drugs: may increase risk of bronchospasm. - Digoxin: may raise serum digoxin levels.